To assess the impact of the Pneumococcal conjugate vaccine catch up campaign among internally displaced populations in the northern Sahel region of Burkina Faso. This effort will implement and evaluate the impact of changing the pneumococcal conjugate vaccine schedule.

To pilot the training of scientists at the first PARMA (PMI-supported Antimalarial Resistance Monitoring in Africa) site in Africa in Senegal.

To support the characterization of non-rotavirus viral diarrheal pathogens to inform the body of work that contributes to optimize the efficacy of rotavirus vaccines.

To strengthen sentinel rotavirus surveillance in Nigeria and Indonesia and enable monitoring of trends in rotavirus hospitalizations pre- and post-vaccine introduction in order to observe the impact of rotavirus vaccines and serve as a platform for case-control evaluations of rotavirus vaccine effectiveness.

To further research how viral ovarian tumor protease activity is critical for replication and host tropism of nairoviruses.

To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) for HIV-uninfected cisgender men and transgender women who have sex with men.

To provide technical assistance to community-based organization partners participating with their local YMCAs in the Vaccine Education project.

To screen a subset of human and mouse monoclonal antibodies for their ability to neutralize GI.1; a time ordered panel of GII.4; and GII.3 noroviruses using a novel human intestinal enteroid cell culture system.

To conduct an evaluation before and two years after the introduction of the Pneumococcal conjugate vaccine (PCV) to study the direct and indirect impact of PCV introduction on vaccine-type pneumococcal carriage among healthy Indonesian children under five years of age.

To further research how viral ovarian tumor protease (vOTU) activity is critical for replication and host tropism of nairoviruses.